- Home
- CPD Activities
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
| Name | INFECTIOUS DISEASES INSTITUTE |
|---|
| Activity Title | Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial |
|---|
| Details | journal club |
|---|
| Competence | General Medicine |
|---|
| Start Date | 01-07-2024 |
|---|
| End Date | 01-07-2024 |
|---|
| Event Time | 08:45 AM |
|---|
| Location | Hybrid |
|---|
| Cost (UGX) | 0 |
|---|
| CPD Points | 1 |
|---|